Skip to main content
ADAPY logo

Adaptimmune Therapeutics plc (ADAPY) Stock Price & Analysis

Adaptimmune Therapeutics plc (ADAPY) — price $0.03 (+27.66%), as of the Nov 19, 2026 trading session; market cap $7.95M.

Educational signal · not a buy or sell recommendation · How to read this

$0.03 +$0.0065 (+27.66%) Market Cap $7.95M

Adaptimmune Therapeutics plc · ADAPY

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing novel T-cell immunotherapies for cancer patients in the US and UK. Leveraging its genetically modified autologous T-cell platform, the company advances therapies like TECELRA for synovial sarcoma, alongside a pipeline targeting various cancers through strategic collaborations, positioning it in the specialized cell therapy market.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.03
Change on the day+27.66%
52-week range$0.001 – $0.07
Market capitalisation$7.95M—
Price / earnings (trailing)0.11
Shares traded on the day514.8K

Price & events

Other perspectives

Council score for Adaptimmune Therapeutics (ADAPY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Strong
Revenue Growth Negative
Debt/Equity Neutral
ROE Negative
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Adaptimmune Therapeutics (ADAPY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Adaptimmune Therapeutics plc (ADAPY) is the company analyzed here. It employs 272 people and is led by Christopher James Hill. In Q1 FY2025 it reported revenue of $7M and net income of -$48M. The market values it at $7.95M.

2 · Latest results

What do the latest results show for Adaptimmune Therapeutics (ADAPY)?

Short answer · as of

The most recent reported quarter, Q1 FY2025, carried revenue of $7M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2025$7M-$48M-$0.19 (diluted)
Q2 FY2025$14M-$30M-$0.11 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Adaptimmune Therapeutics (ADAPY)?

Short answer · as of

The distress and quality screens read Altman Z -15.85 · Piotroski F 0. Trailing ratios: ROA -25.9% · current ratio 2.04.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -15.85 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Adaptimmune Therapeutics (ADAPY)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $20.70M · EPS -0.50 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q1 FY2025) was filed May 13, 2025 — 13 months ago.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$20.70M
EPS estimate
$-0.50

Measured against a quoted price of $0.03 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ADAPY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ADAPY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Adaptimmune Therapeutics (ADAPY)

These answers are editorial: 1 of these 8 answers is drawn from the ADAPY research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is ADAPY a good stock to buy?

Stock Expert AI does not rate ADAPY buy, sell or hold. Adaptimmune Therapeutics plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ADAPY stock price today?

The last price recorded for Adaptimmune Therapeutics plc (ADAPY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the implications of Adaptimmune Therapeutics plc trading on the OTC market?

Trading on the "OTC Other" tier of the OTC market carries several implications for Adaptimmune Therapeutics plc and its investors.

What are the key factors to evaluate for ADAPY?

Evaluate ADAPY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does ADAPY data refresh on this page?

ADAPY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ADAPY's recent stock price performance?

Adaptimmune Therapeutics plc (ADAPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercial-stage product (TECELRA) addressing an unmet medical need in synovial sarcoma. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ADAPY overvalued or undervalued right now?

The trailing P/E of Adaptimmune Therapeutics plc (ADAPY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research ADAPY before investing?

Before investing in Adaptimmune Therapeutics plc (ADAPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP) and 8 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.